Ritalin is okay, Adderall is better.
Okay -- I think it's probably better (and safer) to say that it's possible one drug won't work for you at all, and another might work better. Often it seems many times it's a case of trial and error. Work with your doctor to figure out what works best for You.
For those interested,
here is a link to the Strattera website. Atomoxetine is the generic drug name for Strattera.
Strattera, the first non-stimulant medication that's FDA-approved to treat ADHD in children, adolescents, and adults - available by prescription only.
Here is a link to the Adderall XR website. Adderall is a mix of four amphetamine salts.
Here is a link to the Concerta website. The generic drug name for Concerta is methylphenidate (also know as Ritalin).
The peer reviews pasted below seem to find all options to be effective to treat attention deficit disorders.
In addition to Strattera, Adderall, and Concerta, a much more cost effective (and very commonly prescribed) solution to these patented drugs is generic dextroamphetamine (often referred to as D-amphetamine or simply d-amp).
Ann Pharmacother. 2006 Jun;40(6):1134-42. Epub 2006 May 30.
Atomoxetine versus stimulants for treatment of attention deficit/hyperactivity disorder.Gibson AP, Bettinger TL, Patel NC, Crismon ML.
College of Pharmacy, The University of Texas at Austin, 78712, USA.
OBJECTIVE: To identify, review, and analyze studies comparing atomoxetine with psychostimulants with the intent of determining the role of atomoxetine in the pharmacologic management of attention deficit/hyperactivity disorder (ADHD). DATA SOURCES: Primary, review, and meta-analysis articles were identified by a MEDLINE search (1966-December 2005). MeSH headings used in the search include: attention deficit/hyperactivity disorder, ADHD, atomoxetine, stimulants, psychostimulants, methylphenidate, and amphetamine salts. Relevant data presented at professional meetings that we attended were also identified. STUDY SELECTION AND EXTRACTION: All clinical studies comparing atomoxetine with psychostimulants, regardless of study design, were evaluated. Relevant efficacy and safety data from these studies were included in the discussion. DATA SYNTHESIS: At time of writing, 5 head-to-head trials had compared psychostimulants and atomoxetine in the treatment of ADHD. No significant difference between atomoxetine and methylphenidate immediate-release were found on the ADHD Rating Scale total score. Osmotic oral release system (OROS) methylphenidate showed significantly greater improvement at weeks 1 and 2, and significantly more patients treated with OROS methylphenidate were classified as responders. Patients on both atomoxetine and mixed amphetamine salts extended-release (MAS XR) showed significant improvements at endpoint over baseline; however, Swanson, Kotkin, Agler, M-Flynn, and Pelham (SKAMP) scores were significantly better with MAS XR. Tolerability was similar between atomoxetine and stimulant medications. CONCLUSIONS: Based on available evidence, psychostimulants are regarded as first-line pharmacologic treatment for children and adolescents with ADHD, as the efficacy and safety of these agents have been well established based on clinical trials and extensive naturalistic use. Adverse effects in some patients and abuse potential have led to the search for new treatments. Atomoxetine represents an alternative treatment for ADHD and is unlikely to be associated with abuse; however, long-term safety data are needed to further establish its place in therapy.
PMID: 16735655 [PubMed - indexed for MEDLINE]
Indian J Med Sci. 2005 Dec;59(12):546-55.
Attention deficit hyperactivity disorder--a review for family physicians.Karande S.
Learning Disability Clinic, Division of Pediatric Neurology, Department of Pediatrics, Lokmanya Tilak Municipal Medical College and General Hospital, Sion, Mumbai, India. karandesunil@yahoo.com
Attention deficit hyperactivity disorder (ADHD) is a chronic behavioral disorder characterized by persistent hyperactivity, impulsivity, and inattention that impairs educational achievement and/or social functioning. Its diagnosis is made by ascertaining whether the child's specific behaviors meet the diagnostic and statistical manual of mental disorders-IV-revised criteria. Its etiology is still unclear but recent studies suggest that genetics plays a major role in conferring susceptibility. Comorbidity with psychiatric disorders such as anxiety disorder, depression, oppositional defiant disorder and conduct disorder; and with specific learning disability is not uncommon. Although medication works well in most cases of ADHD, optimal treatment requires integrated medical and behavioral treatment. Methylphenidate (MPH) and atomoxetine are the two drugs being currently prescribed and their efficacy in decreasing the symptoms of ADHD is well documented. Pyschoeducational interventions in school can help increase the successful functioning of affected children and improve their academic performance. Almost half of affected children continue to show significant symptoms of the disorder into adolescence and young adulthood. The family physician can play an important role in detecting this condition early, coordinating its assessment and treatment, counseling the parents and classroom teacher, and monitoring the child's academic and psychosocial progress on a long-term basis.
PMID: 16385176 [PubMed - indexed for MEDLINE]
Am J Health Syst Pharm. 2004 Nov 15;61(22):2391-9.
Atomoxetine: the first nonstimulant for the management of attention-deficit/hyperactivity disorder.Corman SL, Fedutes BA, Culley CM.
Drug Information Center, University of Pittsburgh Medical Center, Pittsburgh, PA 15213, USA.
PURPOSE: The pharmacology, pharmacokinetics, clinical efficacy, safety, drug interactions, dosage and administration, and place in therapy of atomoxetine in the treatment of attention-deficit/hyperactivity disorder (ADHD) are reviewed. SUMMARY: Atomoxetine is a methylphenoxy-benzenepropanamine derivative with antidepressant activity and is thought to enhance noradrenergic function via selective inhibition of the presynaptic norepinephrine transporter. Atomoxetine is rapidly absorbed from the gastrointestinal tract, reaching peak levels in 1.83 hours in pediatric patients and 1-1.5 hours in adults. The clinical efficacy of atomoxetine in the treatment of ADHD has been evaluated in six published clinical trials of children and adolescents and two studies enrolling only adults. Clinical trial data indicate that atomoxetine is safe and well tolerated for the treatment of ADHD; however, safety data about long-term use (greater than one year) are unavailable. Adverse events reported in clinical trials were mainly mild to moderate and transient in nature. Recommended dosing of atomoxetine is weight based, and dosages should be adjusted to a target dosage of 1.2 mg/kg/day in children and adolescents weighing 70 kg or less and to 80 mg/day in children and adolescents weighing over 70 kg and adults. While current guidelines from the American Academy of Pediatrics recommend stimulants and behavior modification as first-line therapy for the management of ADHD, atomoxetine offers those patients who do not respond to or cannot tolerate one or more stimulants an alternative treatment option. CONCLUSION: Atomoxetine, the first non-stimulant approved for the management of ADHD in children, adolescents, and adults, provides patients who have not responded to or cannot tolerate one or more stimulants an alternative treatment option.
PMID: 15581262 [PubMed - indexed for MEDLINE]
Ann Clin Psychiatry. 2002 Jun;14(2):105-11.
Attention deficit disorder in adults.
Pary R, Lewis S, Matuschka PR, Rudzinskiy P, Safi M, Lippmann S.
Department of Veterans Affairs, Mental Health, and Behavioral Science Service, Louisville, Kentucky 40206, USA.
ADHD/ADD, once thought to occur only in children, is now recognized as continuing into adulthood in many people. In order to be labeled as such, signs and symptoms must start before age 7 and are primarily characterized by inattention, distractibility, and impulsiveness. Although the exact mechanism is unknown, a number of associated neurochemical and structural abnormalities have been observed. This disorder can negatively affect the educational, social, and occupational lives of those who suffer from its symptoms. It interferes with the ability to establish and maintain close relationships. Pharmacotherapy remains the primary mode of treatment. Stimulants such as dextroamphetamine and methylphenidate are the main drugs utilized; they are available in immediate and longer duration versions. Bupropion is another important medicinal option, and there are a variety of other miscellaneous medications to consider, including modafinil, venlafaxine, tricyclic antidepressants, and guanfacine. Psychotherapy is shown to help control impulsiveness, form more satisfactory relationships, rear children more effectively, and improve organizational and problem-solving skills.
PMID: 12238735 [PubMed - indexed for MEDLINE]
With respect to the tripling of use of these drugs in clinical practice, I'd say that's mostly likely a side effect of our high pressure society and educational system. Not everyone is happy working their ass off to earn a passing grade; and when individuals learn they can pop this and/or that pill and put the same effort instead and be at the top of the class -- many jump right on board. Many seem to be willing to risk one or two side effects to be more successful in academia or otherwise.
Take care.
Edited by nootropikamil, 08 March 2007 - 02:40 AM.